Souhaitez-vous accéder aux communiqués récents ?

SIOUX FALLS, SOUTH DAKOTA and MINNEAPOLIS, MINNESOTA--(Marketwired - June 20, 2013) - The Sanford Project & DiaMedica (TSX VENTURE:DMA), announced today that their abstract titled...

MINNEAPOLIS, MINNESOTA--(Marketwired - May 1, 2013) - DiaMedica Inc. (TSX VENTURE:DMA) announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a...

MINNEAPOLIS, MINNESOTA--(Marketwired - April 8, 2013) - DiaMedica (TSX VENTURE:DMA), is pleased to announce it has received regulatory approval to commence an anticipated 76 subject Phase...

MINNEAPOLIS, MINNESOTA--(Marketwire - March 22, 2013) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DiaMedica Inc....

MINNEAPOLIS, MINNESOTA--(Marketwire - March 15, 2013) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DiaMedica Inc. (TSX VENTURE:DMA),...

MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 25, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a preliminary short form prospectus in connection with the...

MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 22, 2013) - DiaMedica (TSX VENTURE:DMA) announces today that David Allan has resigned from the Company's board of directors, effective February...

MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 5, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), a biotechnology company focused on developing novel treatments for diabetes, announced that Mr....

MINNEAPOLIS, MINNESOTA--(Marketwire - Jan. 29, 2013) - DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of DM-199 to be utilized in upcoming clinical trials....

MINNEAPOLIS, MINNESOTA--(Marketwire - Jan. 9, 2013) - DiaMedica (TSX VENTURE:DMA) is pleased to announce that Mark Robbins, Ph.D., J.D., has joined as Vice President, Clinical and...